- Global Pharma News & Resources

CD Genomics’s RNA Solutions Division Introduces Dual RNA Sequencing Service

RNA Solutions division belongs to CD Genomics, which offers solutions on the revolutionizing study of RNA, targeting both coding and non-coding RNAs of different physiological functions. The company has updated its technology platform to mainstream NGS, microarray and LC-MS/MS instruments, and its senior bioinformatics scientists have accumulated rich experience in Illumina HiSeq, Agilent microarrays, and QTRAP LC-MS/MS systems. These days, the product manager of CD Genomics announced the Dual RNA Sequencing, which can be an ideal tool for elucidating the molecular dynamics underlying bacterial fitness and host cell phenotype among multiple divergent host cell lineages.


Eukaryotic host cells can be infected by various pathogens, from bacteria to fungi to viruses to parasites including some protozoa. The host-pathogen interaction initiates changes in gene expression in the two interacting organisms, leading to the adaptation and persistence or elimination of the pathogen. The determination of related gene expression changes in host cells and pathogens provides insights into a comprehensive understanding of host-pathogen interactions, including identification of new virulence factors in pathogens and new ways to respond to host pathogen exposure.


“CD Genomics provides dual RNA sequencing services to support researchers, institutes, and biotechnology and pharmaceutical companies all over the world with diverse needs. Dual RNA sequencing is becoming a powerful tool for analyzing host-pathogen interactions in the body, revealing the impact of two organisms on each other. ” said senior scientist at CD Genomics.


Dual RNA-seq is an ideal tool for elucidating the molecular dynamics of bacterial adaptability and host cell phenotypes in many different host cell lineages. It allows simultaneous detection of host- and pathogen-specific transcripts in mixed samples and detection of low-abundance transcripts. The feasibility of this new discovery makes it possible to directly correlate disease-causing gene activity with specific host responses, and to identify pathogenic phenotypes that are not visible in standard virulence assays. This global, sensitive and unbiased method has been successfully applied to a variety of plant pathogen models, and has shown applicability and superiority compared with traditionally used techniques.


“CD Genomics concentrates on supplying high-quality services and products for labs and research institutes. We guarantee the developed products and services, which are customized and can meet the demands of our clients, who believe in our scientists and CD Genomics” said the Market Manager of CD Genomics.


About CD Genomics

CD Genomics has the most advanced next-generation sequencing, microarray, and mass spectrometry technology platforms, providing reliable services for pharmaceutical, biotechnology companies, academia and government agencies, and enjoys a high reputation. CD Genomics is proud to meet the needs of domestic and foreign customers, with customers in more than 50 countries and regions.

Editor Details

Last Updated: 22-Jun-2021